Souhaitez-vous accéder aux communiqués récents ?

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the...

First Quarter 2026 and Selected Highlights:  VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category)VEVYE demand...

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later...

Net Revenue increased 4.5% to $312.0 millionGAAP Net Income increased 188.6% to $1.4 millionAdjusted Net Income decreased 3.6% to $3.4 millionAdjusted EBITDA increased 3.8% to $ $10.1 million LAS...

SHAKOPEE, Minn., May 11, 2026 (GLOBE NEWSWIRE) -- Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC), today reported financial results for the first quarter ended...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent...

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors ...

New York, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape |...

GENFIT today announced that it published the notice of the Combined Shareholders Meeting

CALGARY, ALBERTA, May 11, 2026 (GLOBE NEWSWIRE) -- BASF Agricultural Solutions Canada is proudly marking five years of the BASF Safety Scouts program – an initiative aimed at building the...